Author:
Mirzaei-Behbahani Behnaz,Meratan Ali Akbar,Moosakhani Beitollah,Mohammad-Zaheri Mahya,Mousavi-Jarrahi Zahra,Nikfarjam Nasser,Shahsavani Mohammad Bagher,Saboury Ali Akbar
Abstract
AbstractGreen tea polyphenols (GTPs), particularly epigallocatechin-3-gallate, stand out among natural small molecules screened for their ability to target protein aggregates due to their potent anti-amyloidogenic and neuroprotective activities against various disease-related peptides and proteins. However, the clinical applications of GTPs in amyloid-related diseases have been greatly limited by drawbacks such as poor chemical stability and low bioavailability. To address these limitations, this study utilized an Iranian green tea polyphenolic extract as a reducing agent to neutralize silver ions and facilitate the formation of silver nanoparticle capped by GTPs (GTPs-capped AgNPs). The results obtained from this study demonstrate that GTPs-capped AgNPs are more effective than free GTPs at inhibiting amyloid fibrillation and reducing cytotoxicity induced by amyloid fibrils of human insulin and α-synuclein (α-syn). This improved efficacy is attributed to the increased surface/volume ratio of GTPs-capped AgNPs, which can enhance their binding affinity to amyloidogenic species and boosts their antioxidant activity. The mechanism by which GTPs-capped AgNPs inhibit amyloid fibrillation appears to vary depending on the target protein. For structured protein human insulin, GTPs-capped AgNPs hinder fibrillation by constraining the protein in its native-like state. In contrast, GTPs-capped AgNPs modulate fibrillation of intrinsically disordered proteins like α-syn by redirecting the aggregation pathway towards the formation of non-toxic off-pathway oligomers or amorphous aggregates. These findings highlight polyphenol-functionalized nanoparticles as a promising strategy for targeting protein aggregates associated with neurodegenerative diseases.
Publisher
Springer Science and Business Media LLC
Reference67 articles.
1. Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333–366 (2006).
2. Dobson, C. M. Principles of Protein Folding, Misfolding and Aggregation. In Seminars in Cell & Developmental Biology Vol. 15 3–16 (Academic Press, 2004).
3. Cohen, F. E. & Kelly, J. W. Therapeutic approaches to protein-misfolding diseases. Nature 426(6968), 905–909 (2003).
4. Bartolini, M. & Andrisano, V. Strategies for the inhibition of protein aggregation in human diseases. ChemBioChem 11(8), 1018–1035 (2010).
5. Dhouafli, Z. et al. Inhibition of protein misfolding and aggregation by natural phenolic compounds. Cell. Mol. Life Sci. 75, 3521–3538 (2018).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献